Amoeba SA (ALMIB) AI Stock Analysis

• Market Cap: €65.42M
• Dividend Yield: N/A
• Average Volume (3M): 268.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: N/A
• EPS Growth: 47.13%
• Country: FR
• Employees: 20
• Sector: Services
• Sector Strength: N/A
• Industry: Agricultural Inputs
• EPS (TTM): N/A
• Shares Outstanding: 77,817,220
• 10 Day Avg. Volume: 303,333
• 30 Day Avg. Volume: 268,330
• PEG Ratio: 1.14
• Price to Book (P/B): -13.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.84
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: €0.77 ▼(-28.89% Downside)
• Action: Upgraded Date: 03/27/26
• Date: Action: Upgraded 03/27/26

The score is driven primarily by very weak financial performance (revenue collapse, persistent losses and cash burn, and negative equity with rising debt). Technical indicators add additional downside bias as the stock trades below key moving averages with negative momentum, while valuation provides limited support due to loss-making results and no dividend yield.

Positive Factors

Proprietary biological platform

Owning a proprietary microorganism provides a durable technical moat: unique biological IP can enable differentiated product claims versus chemical treatments, lengthen commercialization timelines for competitors, and support regulatory dossiers and licensing opportunities across ag and industrial markets.

Negative Factors

Revenue collapse in 2025

A full-year revenue collapse erodes scale economics and raises questions on commercial traction and market adoption. Without recurring top-line, fixed-cost absorption, regression to profitable margins is unlikely and recovery will require successful re-commercialization or new revenue streams.

Amoeba SA Business Overview & Revenue Model

Company Description

Amoéba S.A. develops and sells biocidal and fungicide products. It is developing around multiple applications using the amoeba Willaertia magna C2c Maky in the prevention of microbiological risk for water treatment, human wounds, and plant protect...

Read more

Amoéba S.A. develops and sells biocidal and fungicide products. It is developing around multiple applications using the amoeba Willaertia magna C2c Maky in the prevention of microbiological risk for water treatment, human wounds, and plant protect...

How the Company Makes Money

null...

Amoeba SA Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	601.60K	664.31K	0.00	0.00
Gross Profit	0.00	-805.57K	-1.71M	-1.01M	-858.95K
EBITDA	-7.47M	-5.38M	-13.74M	-5.35M	-5.01M
Net Income	-8.30M	-6.59M	-14.30M	-8.02M	-7.82M
Balance Sheet
Total Assets	10.13M	5.65M	6.29M	12.39M	14.50M
Cash, Cash Equivalents and Short-Term Investments	4.72M	458.94K	519.33K	5.53M	7.28M
Total Debt	12.24M	12.07M	4.92M	2.36M	12.50M
Total Liabilities	15.49M	16.06M	10.23M	4.23M	14.30M
Stockholders Equity	-5.36M	-10.41M	-3.94M	8.16M	213.68K
Cash Flow
Free Cash Flow	-7.42M	-4.78M	-12.59M	-5.71M	-6.05M
Operating Cash Flow	-6.13M	-4.22M	-6.50M	-5.40M	-5.90M
Investing Cash Flow	-1.30M	-2.01M	-2.81M	-212.13K	-140.65K
Financing Cash Flow	11.69M	6.16M	4.30M	3.87M	4.98M

Amoeba SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMIB, the sentiment is Negative. The current price of 1.08 is above the 20-day moving average (MA) of 0.94, above the 50-day MA of 0.94, and above the 200-day MA of 0.97, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 39.04 is Neutral, neither overbought nor oversold. The STOCH value of 36.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALMIB.

Amoeba SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COH	73 Outperform	€66.24M	6.23	18.06%	0.55%	6.71%	7.79%
Sector *	55 Neutral	$13.29B	17.42	10.03%	0.93%	7.13%	-12.93%
BIG	44 Neutral	€5.25M	4.91	0.11%	―	-4.10%	-97.02%
ALMIB	42 Neutral	€65.42M	-8.80	―	―	―	47.13%
ALCLA	41 Neutral	€38.91M	6.33	―	―	-0.95%	49.19%
ALATA	38 Underperform	€57.83M	-2.54	-514.29%	―	63.11%	10.97%